Skip to Content
Merck
  • Arsenic trioxide depletes cancer stem-like cells and inhibits repopulation of neurosphere derived from glioblastoma by downregulation of Notch pathway.

Arsenic trioxide depletes cancer stem-like cells and inhibits repopulation of neurosphere derived from glioblastoma by downregulation of Notch pathway.

Toxicology letters (2013-04-02)
Jianing Wu, Zhiyong Ji, Huailei Liu, Yaohua Liu, Dayong Han, Chen Shi, Changbin Shi, Chunlei Wang, Guang Yang, Xiaofeng Chen, Chen Shen, Huadong Li, Yunke Bi, Dongzhi Zhang, Shiguang Zhao
ABSTRACT

Notch signaling has been demonstrated to have a central role in cancer stem-like cells (CSLCs) in glioblastoma multiforme (GBM). We have recently demonstrated the inhibitory effect of arsenic trioxide (ATO) on CSLCs in glioblastoma cell lines. In this study we used neurosphere recovery assay that measured neurosphere formation at three time points to assess the capacity of the culture to repopulate after ATO treatment. Our results provided strong evidence that ATO depleted CSLCs in GBM, and inhibited neurosphere recovery and secondary neurosphere formation. ATO inhibited the phosphorylation and activation of AKT and STAT3 through Notch signaling blockade. These data show that the ATO is a promising new approach to decrease glioblastoma proliferation and recurrence by downregulation of Notch pathway.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Arsenic(III) oxide, 99.995% trace metals basis
Sigma-Aldrich
Arsenic(III) oxide, SAJ first grade, ≥99.0%
Supelco
Arsenic(III) oxide, reference material for titrimetry, certified by BAM, >99.5%
Sigma-Aldrich
Arsenic(III) oxide, ReagentPlus®, ≥99.0%
Sigma-Aldrich
Arsenic(III) oxide, ACS reagent (primary standard)